Latest News Releases

News and features

Epistem received the UKTI's 'Internationalise Your Business' award at the recent Genesis 2009 biotechnology conference in London. UKTI presents this award to the company which it judges has been most successful in expanding into new markets. Nominee companies are established companies who have extended their footprint with UKTI assistance, notably through the UKTI Tradeshow Access Programme. Epistem, led by Matthew Walls CEO,  is extremely pleased to have been honoured with this award which reflects the rapid recent expansion of its business, working with larger pharmaceutical companies in new overseas markets building on the successful presence which it has achieved in the UK.

10/12/2009

Epistem plc will present results from two recently completed clinical studies.  The first study, with a leading pharmaceutical company, demonstrates androgen receptor pathway activity in hair from elderly volunteers. In the second phase I study, novel pharmacodynamic markers for Enzon Pharmaceuticals Inc’s survivin messenger ribonucleic acid (mRNA) antagonist were identified from hair follicle analysis. Data will be presented in poster sessions at the AACR-NCI-EORTC “Molecular Targets and Cancer Therapeutics” Conference, Boston on Monday 16^th November and Wednesday 18th November 2009.

8/11/2009

In studies sponsored by the National Institutes of Health's National Institute for Allergy and Infectious Diseases, Aeolus drug AEOL 10150 effectively increases regeneration of GI stem cells and reduces the severity and duration of diarrhea and the drug improves survival when administered 24 hours after total body irradiation.

22/10/2009

MANCHESTER, UNITED KINGDOM --(Marketwire- October 19 2009) - Epistem Plc (LSE: EHP), the leading UK biotechnology company, will open a US office based in Boston, MA to increase its presence in the all important North American Market. The US office (‘Epistem Inc’) will maximise the awareness of Epistem Plc’s technology offering as well as support the commercialisation of the recently launched proprietary GenetRx^TM biomarker platform in oncology.

19/10/2009

MANCHESTER, ANGLETERRE, June 18 /PRNewswire/-- Epistem plc (LSE:EHP), l'entreprise anglaise de biotechnologie et de contrats de service annonce aujourd'hui son accrèditation par le gouvernement français au Crèdit d'Impôt Recherche. Par consèquent, les entreprises françaises pourront dèsormais bènèficier 'une rèduction de taxes pour tout projet de recherche entrepris avec Epistem.

18/6/2009

MANCHESTER, UNITED KINGDOM --(Marketwire-June 2 2009) - Epistem plc (LSE: EHP), the UK biotechnology and contract research company, will present preclinical results from its recently completed plucked hair biomarker study at the Institute of Cancer Research Centenary Conference, in Queen Elizabeth II Conference Centre, London, UK on 8^th to 10^th June 2009.  This study was completed successfully on gemcitabine, commonly known as Gemzar.

2/6/2009

MANCHESTER, UNITED KINGDOM - Epistem plc (LSE: EHP), the UK biotechnology and contract research company, have presented results from their latest plucked hair biomarker study at the AACR Meeting in Denver, Colorado on Sunday 19^th April.

28/4/2009

MANCHESTER, UNITED KINGDOM --(Marketwire-April 14 2009) - Epistem plc (LSE: EHP), the UK biotechnology and contract research company, will present results from its recently completed preclinical plucked hair biomarker study at the American Association for Cancer Research (AACR) 100^th Annual Meeting in Denver, Colorado on Sunday 19^th April 2009

14/4/2009

Manchester, UK, 2^nd March 2009 - Epistem Plc (LSE:EHP) the UK biotechnology and research services company announced today that they have signed a research and development collaboration with Novartis to identify new drug targets and therapeutics across a variety of disease areas.

2/3/2009